Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

Tomas Kalincik; Vino Vivek; Vilija Jokubaitis; Jeannette Lechner-Scott; Maria Trojano; Guillermo Izquierdo; Alessandra Lugaresi; Francois Grand'Maison; Raymond Hupperts; Celia Oreja-Guevara; Roberto Bergamaschi; Gerardo Iuliano; Raed Alroughani; Vincent Van Pesch; Maria Pia Amato; Mark Slee; Freek Verheul; Ricardo Fernandez-Bolanos; Marcela Fiol; Daniele La Spitaleri; Edgardo Cristiano; Orla Gray; Jose Antonio Cabrera-Gomez; Vahid Shaygannejad; Joseph Herbert; Steve Vucic; Merilee Needham; Tatjana Petkovska-Boskova; Carmen-Adella Sirbu; Pierre Duquette; Marc Girard; Pierre Grammond; Cavit Boz; Giorgio Giuliani; Maria Edite Rio; Michael Barnett; Shlomo Flechter; Fraser Moore; Bhim Singhal; Elizabeth Alejandra Bacile; Maria Laura Saladino; Cameron Shaw; Eli Skromne; Dieter Poehlau; Norbert Vella; Timothy Spelman; Danny Liew; Trevor J Kilpatrick; Helmut Butzkueven

Journal article

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

Tomas Kalincik, Vino Vivek, Vilija Jokubaitis, Jeannette Lechner-Scott, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Francois Grand'Maison, Raymond Hupperts, Celia Oreja-Guevara, Roberto Bergamaschi, Gerardo Iuliano, Raed Alroughani, Vincent Van Pesch, Maria Pia Amato, Mark Slee, Freek Verheul, Ricardo Fernandez-Bolanos, Marcela Fiol, Daniele La Spitaleri Show all

BRAIN | OXFORD UNIV PRESS | Published : 2013

DOI: 10.1093/brain/awt281

Download PDF

Abstract

The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis relapses; assess the relationship between sex and primary progressive disease course; and compare effects of age and disease duration on relapse incidence. Annualized relapse rates were calculated using the MSBase registry. Patients with incomplete data or <1 year of follow-up were excluded. Patients with primary progressive multiple sclerosis were only included in the sex ratio analysis. Relapse incidences over 40 years of multiple sclerosis or 70 years of age were compared between females and males with Andersen-Gill and Tweedie models. Female-to-male ratios stratified by annual relapse count were e..

View full abstract

University of Melbourne Researchers

Trevor Kilpatrick Author Florey Department of Neuroscience and Mental Health

Danny Liew Author Medicine - Royal Melbourne Hospital

Timothy Spelman Author Surgery - St Vincent's Hospital

John King Author Medicine - Royal Melbourne Hospital

Helmut Butzkueven Author Medicine - Royal Melbourne Hospital

Related Projects (5)

Multiple Sclerosis: Investigating the cause and differences in outcome

nan

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

Is MS treatment effective long-term?

Multiple Sclerosis is an illness affecting more than 20,000 Australians, and causes significant disability and social disruption in most suf..

Multiple Sclerosis: Investigating the cause and differences in outcome

nan

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

Grants

Awarded by Multiple Sclerosis Research Australia

Awarded by NHMRC

Awarded by NHMRC Centre for Research Excellence

Funding Acknowledgements

The work was supported by the Multiple Sclerosis Research Australia Postdoctoral Fellowship to TK [11-054], NHMRC Career Development Award (Clinical) to H.B. [ID628856], NHMRC Project Grant [1032484], NHMRC Centre for Research Excellence [Grant ID 1001216] and the MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer-Schering, Sanofi-Aventis and BioCSL.